| Jeremy Davis |
Jeremy Davis is currently working as the Chief Commercial Officer & Senior Vice President at Standard BioTools, Inc. He started this position in 2022. Mr. Davis has an undergraduate degree from the University of Oklahoma. He also holds an MBA from the Weatherhead School of Management. |
| Thomas D. Carey |
Thomas D. Carey is the founder of Perspective Group LLC, which was founded in 2015. He is currently the Chairman of Standard BioTools, Inc. and a Trustee at Catholic Charitable Bureau of the Archdiocese of Boston, Inc. He has previously held positions as Chairman of Vital Biosciences, Inc., Independent Director at EXACT Sciences Corp., and Independent Director at SomaLogic, Inc. He was also a Partner & Head-Global Life Sciences Practice at Russell Reynolds Associates, Inc. and a Member at Spencer Stuart, Inc. Mr. Carey received his undergraduate degree from the College of the Holy Cross (Massachusetts) and his graduate degree from Kellogg School of Management. |
| Agnieszka M. Gallagher |
Agnieszka M. Gallagher is currently the Secretary & Chief Compliance Officer at ViiV Healthcare Ltd. and the Chief Legal Officer & Senior Vice President at Standard BioTools, Inc. She previously worked as the Secretary, Chief Compliance Officer & Executive VP at OraSure Technologies, Inc. and as the Chief Ethics & Compliance Officer at Alnylam Pharmaceuticals, Inc. Ms. Gallagher obtained her undergraduate and graduate degrees from Rutgers State University of New Jersey and her graduate degree from Rutgers Law School. |
| Elizabeth R. Jensen |
Elizabeth R. Jensen is currently the Chief Human Resources Officer at Standard BioTools, Inc. Prior to this, she was the Chief Human Resources Officer & Vice President at Gibraltar Industries, Inc. and the VP-Human Resources & Internal Communications at Hach Co. She completed her undergraduate degree at San Jose State University. |
| Shane Bowen |
Shane Bowen is the founder of Palamedrix, Inc. He currently holds the position of Chief Technology Officer at Standard BioTools, Inc. |
| Adam Taich |
Adam Taich is currently the Chief Strategy Officer at Standard BioTools, Inc. He previously worked as the VP & General Manager-Molecular Biology at Thermo Fisher Scientific (Asheville) LLC from 2004 to 2021 and as the Chief Executive & Business Officer at SomaLogic, Inc. from 2021 to 2024. He obtained his undergraduate degree from Miami University. |
| Hanjoon Alex Kim |
Hanjoon Alex Kim's current job(s) include being the Director at SomaLogic, Inc. since 2024 and the Chief Operating Officer at Standard BioTools, Inc. since 2022. Mr. Kim's former job(s) include being the VP-Business Development Water Quality Group at Danaher Corp. from 2002 to 2012, the Senior Vice President-Corporate Strategy at Pall Corp. from 2012 to 2015, and the Executive VP & President-Healthcare Division at Milliken & Co. (South Carolina) from 2015 to 2021. Mr. Kim's education history includes an undergraduate degree from Carnegie Mellon University, an MBA from Stanford University, and a graduate degree from the University of Pittsburgh. |
| Stephen Alaric Williams |
Stephen Alaric Williams is the founder of Decisionability LLC, which was founded in 2007. He is currently the Chief Medical Officer at SomaLogic Operating Co., Inc. since 2009 and at Standard BioTools, Inc. He has also held the position of Director at Riot Platforms, Inc. in 2013 and Vice President & Head-Clinical Technology at Pfizer Inc. from 1989 to 2007. Additionally, he was a Principal at Pfizer Ltd. in 1993. Dr. Williams received a doctorate degree from Charing Cross Hospital Medical School. |
| David A. King |
David A. King is currently working as the Senior VP-Global Research & Development at Standard BioTools, Inc. He previously worked as a Member at HP, Inc., a Principal at Agilent Technologies, Inc., and a Senior Vice President-Research & Development at Standard BioTools, Inc. He also held positions as the Head-New Product Development at iolon, Inc., Vice President-Product Development at Guava Technologies, Inc., and Vice President-Product Development at Affymetrix, Inc. Dr. King obtained a doctorate degree from Stanford University. |
| Jeffrey G. Black |
Jeffrey G. Black is currently a Director at Cellana, Inc., a Director at Cellana LLC, a Director at SomaLogic, Inc., and the Chief Financial Officer & Senior Vice President at Standard BioTools, Inc. He has also held positions as the Chief Financial Officer at Lpath Therapeutics, Inc., Apollo Endosurgery International LLC, and Chiron Mimotopes Peptide Systems LLC. In the past, he worked as the Executive Director-Accounting & Controller at Ionis Pharmaceuticals, Inc., Controller at Triteal Corp., Vice President & Controller at Clarent Corp., Controller at Lightspan, Inc., Executive VP, Chief Financial & Accounting Officer at Alphatec Holdings, Inc., Chief Financial Officer at AltheaDx, Inc., Vice President & Controller at Accelerated Networks, Inc., Chief Financial Officer & Executive Vice President at Alphatec Spine, Inc., Chief Accounting Officer & Senior Vice President at Verenium Corp., Principal at Regent Pacific Management Corp., and Chief Financial Officer at Applied Proteomics, Inc. He received his undergraduate degree from the University of Arizona in 1991. |
| Michael Egholm |
Michael Egholm was the founder of Danaher Corp. (founded in 2017) where he held the title of Chief Technology Officer-Danaher Life Sciences from 2017 to 2021. He is currently the President, Chief Executive Officer & Director at Standard BioTools, Inc. (since 2022) and the President, CEO, Secretary, Treasurer & Director at SomaLogic, Inc. (since 2024). He is also a Director at Abbratech, Inc. and a Member of the Royal Danish Academy of Sciences & Letters. In his former positions, he served as an Independent Director at IsoPlexis Corp. (2018-2022), President-Biopharmaceuticals at Pall Corp. (2014-2017), Vice President-Research at Molecular Staging, Inc., and Chief Technology Officer at 454 Life Sciences Corp. He also held the position of Chief Technology Officer at Roche Applied Science from 2008 to 2010. Dr. Egholm obtained a doctorate degree from the University of Copenhagen. |
| Franklin R. Witney |
Franklin R. Witney is currently the Chairman at Gyros AB, Gyros Protein Technologies AB, Canopy Biosciences LLC, Jumpcode Genomics, Inc., Telesis Bio, Inc., Cerus Corp., Revvity, Inc., Standard BioTools, Inc., Genoptix, Inc., One Lambda, Inc., Revvity BV, Nexcelom Bioscience LLC, RareCyte, Inc., Emulate, Inc., and Leinco Technologies, Inc. He previously held positions as the President, Chief Executive Officer & Director at Dionex Corp. from 2009 to 2011, President, Chief Executive Officer & Director at Affymetrix, Inc. from 2011 to 2016, President & Chief Executive Officer at Panomics LLC from 2002 to 2008, and Operations Manager-Life Science Group at Bio-Rad Laboratories, Inc. from 1983 to 2000. Dr. Witney also served as the Chief Commercial Officer & Executive VP at Affymetrix, Inc. from 2008 to 2009 and President & Chief Operating Officer at Packard BioScience Co. from 2000 to 2001. He has a doctorate degree from Indiana University and an undergraduate degree from the University of Illinois. |
| Fenel M. Eloi |
Fenel M. Eloi is currently an Independent Director at Standard BioTools, Inc., 908 Devices, Inc., Ultivue, Inc., and a Director at Vaxess Technologies, Inc. He is also a Director at Mitotherapeutix LLC, Complete Care IT LLC, Museum of Science, and a Managing Partner at P&M Capital Partners LLC. Previously, he worked as a Director at BioHelix Corp. from 2009 to 2013, Chief Financial Officer at Oscient Pharmaceuticals Corp. from 1989 to 1991, Chief Financial Officer & Senior Vice President at LifeCell Corp., Principal at Haemonetics Corp., and Chief Operating & Financial Officer at Interleukin Genetics, Inc. He also served as the Chief Operating & Financial Officer at Cell Signaling Technology, Inc. from 2006 to 2018. Mr. Eloi holds an MBA from Anna Maria College and an undergraduate degree from Lee University. |
| Eli D. Casdin |
Eli D. Casdin founded Casdin Capital LLC in 2012, where he is working as Chief Investment Officer from 2022 and Casdin Capital in 2011, where he is working as Chief Investment Officer from 2011. Mr. Casdin also currently works at Standard BioTools, Inc., as Independent Director from 2022, SomaLogic Operating Co., Inc., as Director from 2020, The Rockefeller University, as Director from 2021, and various other companies. Mr. Casdin also formerly worked at CM Life Sciences, Inc., as Chief Executive Officer & Director from 2020 to 2021, CM Life Sciences II, Inc., as Chief Executive Officer & Director in 2021, CM Life Sciences III, Inc., as Chief Executive Officer & Director in 2021, and various other companies. Mr. Casdin received his undergraduate degree in 2003 from The Trustees of Columbia University in The City of New York and Masters Business Admin degree in 2003 from Columbia Business School. |
